AIDS-related systemic non-Hodgkin's lymphoma at a large community program

Area of Science:

• Oncology
• Infectious Diseases
• Immunology

Background:

• Triple antiretroviral therapy (ART) has decreased opportunistic diseases in HIV-infected individuals.
• The impact of ART on the clinical presentation and outcomes of AIDS-related systemic non-Hodgkin's lymphoma (NHL) remains unclear.
• Understanding these effects is crucial for managing HIV-associated malignancies.

Purpose of the Study:

• To investigate the incidence and clinical features of systemic NHL in HIV-infected patients.
• To compare the characteristics and outcomes of systemic NHL across different antiretroviral therapy regimens.
• To assess the influence of triple ART on the development and progression of AIDS-related NHL.

Main Methods:

• Retrospective analysis of 76 HIV-infected patients diagnosed with systemic NHL between 1996 and 2000.
• Patients were categorized into three groups based on antiretroviral therapy history: treatment-naive, dual nucleoside, and triple ART.
• Clinical data, including CD4+ cell counts, HIV RNA viral load, chemotherapy completion, and survival, were analyzed.

Main Results:

• Systemic NHL occurred in 76 of 3655 HIV-infected patients.
• Patients on triple ART showed a longer median duration of therapy before NHL diagnosis (12 months) compared to dual nucleoside (8 months).
• Thirty-five percent of triple ART patients had viral loads <400 copies/ml and a median CD4+ count of 301 cells/mm³ at NHL diagnosis; they were more likely to complete chemotherapy, but overall survival did not differ significantly across groups.

Conclusions:

• AIDS-related systemic NHL continues to be diagnosed in patients receiving triple ART.
• This malignancy remains associated with significant mortality, underscoring the need for improved understanding of its pathogenesis.
• Further research into the mechanisms driving NHL development in treated HIV patients is warranted.